A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects with Psoriatic Arthritis.

Trial Profile

A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects with Psoriatic Arthritis.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Perakizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Aug 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
    • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Oct 2011 Status changed from recruiting to active, no longer recruiting; enrollment was completed in quarter 3 of 2011 according to a Roche presentation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top